🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-523965-97-00
Authorised Phase II

The Expression of Fibroblast Activation Protein in Patients with Non-Small Cell Lung Cancer Patients

2025-523965-97-00 · tracked via the Priya Life Science EU tracker
Sponsor
Turku University Hospital
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Neoplasms
Decision date
16/12/2025
Enrollment target
60
Sites
Finland

Condition studied

Non small cell lung cancer

Investigational medicinal product(s)

[18F]FAPI-74

Eligibility

Age group
18-64 years
Sex
Female, Male

Primary endpoint

SUVmax, SUVmean and SUVpeak of the primary tumor, tumor recurrence, lymph node metastasis or distant metastasis

Endpoint detail

Histological confirmation of cancer in lesions with FAPI PET -imaging

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523965-97-00 on CTIS ↗ ← All trials in the EU